The team is now conducting additional studies of mNGS in plasma, as well as looking to reduce turnaround time by running the test on a nanopore sequencer.
Variantyx, a 2014 spinout from Tel Aviv University that is based in Framingham, Massachusetts, provides clinical genomic testing for screening and rare disease diagnostics.
Olaparib maintenance therapy stretched out progression-free survival, suggesting a need for germline BRCA1/2 mutation testing in pancreatic cancer patients.
The firm plans to use proceeds to fund commercial activities related to its ClonoSeq assay, as well as research into drug discovery and its project to map TCR antigens.
The team evaluated various technologies in an attempt to develop a framework to compare future methods against and to serve as a guide for researchers.
The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
